Alternative Funding Task Force; create from members of the Mississippi Rare Disease Advisory Council.
Senate Bill 2756 creates a temporary task force to study how “alternative funding programs” affect patients’ access to affordable prescription drugs in Mississippi. The task force is intended to examine whether these programs help or hinder access to medically necessary medications, with a particular focus on rare disease patients and the broader prescription drug market. Its membership would come from the Mississippi Rare Disease Advisory Council, or designees appointed by council members, and the physician member of that council with rare disease experience would serve as chair.
The study is required to cover the history and prevalence of alternative funding programs, how those programs operate as a business model, and their effects on patient assistance programs and prescription coverage. The bill specifically directs the task force to consider impacts on commercial insurance, public employee health plans, and the state health insurance exchange. The task force must meet by May 15, 2025, complete its work by December 1, 2025, and then submit its findings and any legislative recommendations to state officials, legislative committees, and several stakeholder organizations before terminating.
The bill does not directly change insurance or pharmacy law; instead, it creates a short-term advisory body under the Mississippi Rare Disease Advisory Council framework to gather information and recommend future legislation. It would require coordination among health policy stakeholders and produce a report for the Governor, Medicaid leadership, and relevant House and Senate committees. The practical legal effect is to establish a formal study process that could lead to later statutory or regulatory changes affecting prescription drug coverage, patient assistance programs, and insurance benefit design.
Based on the bill text and available context, the measure appears generally informational and policy-oriented rather than controversial on its face. The inclusion of a broad set of recipients for the final report, including medical, pharmacy, employer, and pharmaceutical industry groups, suggests an effort to gather input from multiple sides of the issue. No committee transcript or recorded vote is provided, so there is no documented public debate or formal vote sentiment in the available materials.
The likely point of contention is the role of alternative funding programs in prescription drug coverage: supporters may view them as a cost-management tool, while critics may argue they can interfere with patient assistance programs, specialty drug access, or coverage stability. The bill’s focus on rare disease patients and its request to study effects on commercial, public employee, and exchange plans indicate concern that these programs may shift costs or reduce access for patients needing high-cost medications. Stakeholders most likely to hold differing views include patient advocates, independent pharmacies, pharmacy benefit managers, pharmaceutical manufacturers, insurers, employers, and Medicaid policymakers.